p16(INK4) gene mutation and allelic loss of chromosome 9p21-22 in Taiwanese hepatocellular carcinoma

Anticancer Research

Volumn 20, Issue 3 A, 2000, Pages 1621-1626

  Chen, Tse Ching ^a,b   Hsieh, Ling Ling ^a   Kuo, Tseng Tong ^a   Ng, Kwai Fong ^a   Chou, Yah Huei Wu ^a   Jeng, Long Bin ^a   Chen, Miin Fu ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

CDKN2A; Chromosome 9p; Hepatocellular carcinoma; Homozygous deletion; Loss of heterozygosity; MTS1; Mutation; p16(INK4)

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; MICROSATELLITE DNA; PROTEIN P16; CARRIER PROTEIN; DNA; PROTEIN P16INK4A;

ADULT; AGED; ALLELE; ARTICLE; CHROMOSOME 9P; CLINICAL ARTICLE; CODON; DELETION MUTANT; DNA SEQUENCE; EXON; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; NUCLEIC ACID BASE SUBSTITUTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TAIWAN; CHROMOSOME 9; CHROMOSOME DELETION; CHROMOSOME MAP; GENETICS; LIVER TUMOR; MIDDLE AGED; MUTATION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CHROMOSOME DELETION; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, NEOPLASM; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TAIWAN;

EID: 0033624490     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Anthony PP: Tumours and Tumour-Like Lesions of the Liver and Biliary Tract. In: MacSween RNM, Anthony PP, Scheuer PJ, Burt AD, Portmann BC. Pathology of the Liver, third edition. New York: Churchill Livingstone, 635-712, 1994.
2. Ding SF and Habib NA: Loss of heterozygosity in liver tumors. J Hepatol 22: 30-38, 1995.
3. Wu Chou YH, Chung KC, Jeng LB, Chen TC and Liaw YF: Frequent allelic loss on chromosome 4q and 16q associated with human hepatocellular carcinoma in Taiwan. Cancer Lett 123: 1-6, 1998.
4. Bressac B, Kew M, Wands J and Ozturk M: Selective G to T mutation of the p53 gene in hepatocellular carcinoma from Southern Africa. Nature 350: 429-431, 1991.
5. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NF and Harris CC: Mutational hotspot in the p53 gene in human hepatocellular carcinoma: Nature 350: 427-428, 1991.
6. Buetow KH, Sheffield VC, Zhu M, Zhou T, Shen FM, Hino O, Smith M, McMahon BJ, Lanier AP, London WT, Redeker AG and Govindarajan S: Low frequency of the p53 mutations observed in a diverse collection of hepatocellular carcinomas. Proc Natl Acad Sci USA 89: 9622-9626, 1992.
7. Nishida N, Fukuda Y, Kokuryu H, Toguchida J, Yandell DW, Ikenega M, Imura H, Ishizaki K: Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res 53: 368-372, 1993.
8. Oda T, Tsuda H, Scarpa A, Sakamoto M and Hirohashi S: p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 52: 6358-6364, 1992.
9. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE and Skolnick MH: A cell cycle regular potentially involved in genesis of many tumor types. Science 264: 436-440, 1994.
10. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993.
11. Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, Titus-Ernstoff L, Bouchard B, Vijayasaradhi S, Houghton AN, Lahti J, Kidd VJ, Housman DE and Dracopoli NC: Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 89: 10557-10561, 1992.
12. Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, Singh AD, Shields JA, Shields CL, Croce CM and Huebner K: Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res 54: 5269-5274, 1994.
13. Merlo A, Gabrielson E, Askin F and Sidransky D: Frequent loss of chromosome 9 in human primary non-small cell lung cancer. Cancer Res 54: 640-642, 1994.
14. Hayashi N, Sugimoto Y, Tsuchiya E, Ogawa M and Kamura Y: Somatic mutations of the MTS (multiple tumor suppressor )/CDK41 (cyclin dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Commun 202: 1426-1430, 1994.
15. Yoshida S, Todoroki T, Ichikawa Y, Hanai S, Suzuki H, Hori M, Fukao K, Miwa M and Uchida K: Mutations of the p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res 55: 2756-2760, 1995.
16. Caldas C, Hahn S, da Costa LT, Redston M, Schutte M, Seymour A B, Weinstein CL, Hruban RH, Yeo CJ and Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1 ) gene in pancreatic adenocarcinoma. Nat Genet 8: 27-32, 1994.
17. Sakata K, Tamura G, Maesawa C, Suzuki Y, Terashima M, Satoh K, Eda Y, Suzuki A, Sekiyama S and Satodate R: Loss of heterozygosity on the short arm of chromosome 9 without p16 gene mutation in gastric carcinomas. Jpn J Cancer Res 86: 333-335, 1995.
18. Aoki T, Mori T, Du X, Nishira T, Matsubara T and Nakamura Y: Allelotype study of esophageal carcinoma. Genes Chromosomes Cancer 10: 177-182, 1994.
19. Mori T, Miura K, Aoki T, Nishihira T, Mori S and Nakamura Y: Frequent somatic mutations of the MTSI/CDK4I (multiple tumor suppressor /cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54: 3396-3397, 1994.
20. Nobori T, Miura K, Wu D, Lois A, Takabayashi K and Carson D: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756, 1994.
21. Cairns P, Tokino K, Eby Y and Sidransky D: Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res 54: 1422-1424, 1994.
22. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D and Sidransky D: Frequency of homozygous deletions at p16/CDKN2 in primary tumors. Nat Genet 11: 210-212, 1995.
23. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH and Harris CC: Mutation and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 91: 11045-11049, 1994.
24. Li YJ, Hoang-Xuan K, Delattre JY, Poisson M, Thomas G and Hamelin R: Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene 11: 597-600, 1995.
25. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692, 1995.
26. Lo KW, Cheung ST, Leung SF, van Hasselt A, Tsang YS, Mak KF, Chung YF, Woo JK, Lee JC and Huang DP: Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 56: 2721-2725, 1996.
27. Qin L, Tang Z, Liu K, Ye S, He B, Zhang Y and Zhou G: Alterations of CDKN2 (p16/MTS1) exon 2 in human hepatocellular carcinoma. Oncol Rep 3: 405-408, 1996.
28. Biden K, Young J, Buttenshaw R, Searle J, Cooksley G, Xu DB and Leggett B: Frequency of mutation and deletion of the tumor suppressor gene CDKN2A(MTS1/p16) in hepatocellular carcinoma from an Australian population. Hepatology 25: 593-597, 1997.
29. INK4A gene in liver cancer. Int J Cancer 67: 176-180, 1996.
30. Piao Z, Park C, Lee JS, Yang CH, Choi KY and Kim H: Homozygous deletion of the CDKN2 gene and loss of heterozygosity of 9p in primary hepatocellular carcinoma. Cancer Lett 122: 201-207, 1998.
31. Hui AM, Sakamoto M, Kanai Y, Ino Y, Gotoh M, Yokota J and Hirohashi S: Inactivation of p16INK4 in hepatocellular carcinoma. Hepatology 24: 575-579, 1996.
32. Chaubert P, Gayer R, Zimmermann A, Fontolliet C, Stamm B and Bosman F: Germline mutation of the p16INK4 (MTS1) gene occur in a subset of patients with hepatocellular carcinoma. Hepatology 25: 1376-1381, 1997.
33. Bonilla F, Orlow I and Cordon-Cardo C: Mutational study of p16/CDKN2/MTS1/INK4A and p57/KIP2 genes in hepatocellular carcinoma. Int J Oncol 12: 583-588, 1998.
34. Lin YW, Chen CH, Huang GT, Lee PH, Wang JT, Chen DS, Lu FJ and Sheu JC: Infrequent mitations and no methylation of CDKN2A (p16.MTS1) and CDKN2B(p15/MTS2) in hepatocellular carcinoma in Taiwan. Eur J Cancer 34: 1789-1795, 1998.
35. van der Riet P, Nawroz H, Corio R, Tokino K, Koch W and Sidransky D: Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 54: 1156-1158, 1994.
36. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, Nobori T, Olopade OI, Buckler AJ and Testa JR: p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54: 5547-5551, 1994.
37. Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, Hsu HC, Chuang CN, Yang PC, Wang TH, Lin JT and Lee CZ: Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 89: 259-266, 1985.
38. Nagai H, Pineau P, Tiollais P, Buendia MA and Dejean A: Comprehensive allelolyping of human hepatocellular carcinoma. Oncogene 14: 2927-2933, 1997.